Brief: Jane Huang, M.D. Joins Prelude Therapeutics As President And Chief Medical Officer
09/03/2022 13:10
March 9 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* JANE HUANG, M.D., JOINS PRELUDE THERAPEUTICS AS PRESIDENT AND CHIEF
MEDICAL
OFFICER
Source text for Eikon: ID:nGNX21zF0H
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview